Publications

Detailed Information

Heart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer

DC Field Value Language
dc.contributor.authorJang, Bum-Sup-
dc.contributor.authorCha, Myung-Jin-
dc.contributor.authorKim, Hak Jae-
dc.contributor.authorOh, Seil-
dc.contributor.authorWu, Hong-Gyun-
dc.contributor.authorKim, Eunji-
dc.contributor.authorKim, Byoung Hyuck-
dc.contributor.authorKim, Jae Sik-
dc.contributor.authorChang, Ji Hyun-
dc.date.accessioned2024-05-14T01:26:50Z-
dc.date.available2024-05-14T01:26:50Z-
dc.date.created2021-03-04-
dc.date.created2021-03-04-
dc.date.created2021-03-04-
dc.date.issued2020-11-
dc.identifier.citationRadiotherapy and Oncology, Vol.152, pp.126-132-
dc.identifier.issn0167-8140-
dc.identifier.urihttps://hdl.handle.net/10371/201656-
dc.description.abstractIntroduction: We evaluated the incidence of cardiac events after chemoradiotherapy in patients with stage III non-small cell lung cancer (NSCLC) based on baseline cardiovascular risk and the heart substructures' radiation dose. Methods: From 2008 to 2018, the cardiac events of 258 patients with stage III NSCLC who received definitive chemoradiotherapy were reviewed. The 10-year cardiovascular risk was calculated using the Atherosclerotic Cardiovascular Disease (ASCVD) scoring system. Dose-volume histograms were estimated for each cardiac chamber. A multivariate competing-risk regression analysis was conducted to assess each cardiac event's subhazard function (SHR). Results: The median follow-up was 27.5 months overall and 38.9 months for survivors. Among the 179 deaths, none was definitely related to cardiac conditions. Altogether, 32 cardiovascular events affected 27 patients (10.5%) after chemoradiotherapy. Ten were major cardiac adverse events, including heart failure (N = 6) and acute coronary syndrome (ACS, N = 4). Most cardiovascular events were related to well-known risk factors. However, the volume percentage of the left ventricle (LV) receiving 60 Gy (LV V60) > 0 was significantly associated with ACS (SHR = 9.49, 95% CI = 1.28-70.53, P = 0.028). In patients with high cardiovascular risk (ASCVD score > 7.5%), LV V60 > 0% remained a negative ACS prognostic factor (P = 0.003). Meanwhile, in patients with low cardiovascular risk, the LV radiation dose was not associated with ACS events (P = 0.242). Conclusions: A high LV radiation dose could increase ACS events in patients with stage III NSCLC and high cardiovascular risk. Pre-treatment cardiac risk evaluation and individualized surveillance may help prevent cardiac events after chemoradiotherapy. (C) 2020 Elsevier B.V. All rights reserved.-
dc.language영어-
dc.publisherElsevier BV-
dc.titleHeart substructural dosimetric parameters and risk of cardiac events after definitive chemoradiotherapy for stage III non-small cell lung cancer-
dc.typeArticle-
dc.identifier.doi10.1016/j.radonc.2020.09.050-
dc.citation.journaltitleRadiotherapy and Oncology-
dc.identifier.wosid000594802900021-
dc.identifier.scopusid2-s2.0-85094574898-
dc.citation.endpage132-
dc.citation.startpage126-
dc.citation.volume152-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorKim, Hak Jae-
dc.contributor.affiliatedAuthorOh, Seil-
dc.contributor.affiliatedAuthorWu, Hong-Gyun-
dc.contributor.affiliatedAuthorKim, Byoung Hyuck-
dc.type.docTypeArticle-
dc.description.journalClass1-
dc.subject.keywordPlusASSOCIATION TASK-FORCE-
dc.subject.keywordPlusDOSE-ESCALATION TRIALS-
dc.subject.keywordPlusAMERICAN-COLLEGE-
dc.subject.keywordPlusRADIOTHERAPY-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusDISEASE-
dc.subject.keywordPlusMORTALITY-
dc.subject.keywordPlusTOXICITY-
dc.subject.keywordAuthorChemoradiotherapy-
dc.subject.keywordAuthorCardiac event-
dc.subject.keywordAuthorDosimetry-
dc.subject.keywordAuthorHeart substructure-
dc.subject.keywordAuthorLung cancer-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Related Researcher

Kim, Byoung hyuck Image

Kim, Byoung hyuck김병혁
(기금)조교수
  • College of Medicine
  • Department of Medicine
Research Area 소화기암, 육종, 폐암

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share